Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseobservationalRules rewrite

A Study in Greece Observing How Patients With Stomach and Esophageal Cancer Are Diagnosed and Treated in Ev…

This is a retrospective-prospective watch-and-measure (no experimental treatment required), multicenter, single-country study aiming to describe the epidemiological characteristics and management strategies in patients with stage II-IVB gastric/GEJ adenocarcinoma in routine clinical practice in Greece.

Official registry: https://clinicaltrials.gov/study/NCT07800754 · AstraZeneca · enrollment listed as 300

What this phase means

This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.

They plan to enroll about 300 people at 6 sites. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

Epidemiological Characteristics And Management Strategies Of Gastric/Gastrophaegal Junction Cancer Patients In Routine Clinical Practice: A Greek Multicenter Observational Study (The GRACE Study)

Primary outcome (registry wording): Distribution of GC/GEJ cancer types

Who it is for (from inclusion criteria)

  • Ages 18 Years to 130 Years
  • Patients aged ≥18 years upon gastric/GEJ adenocarcinoma diagnosis
  • Patients diagnosed with histologically confirmed, stage II to IVB adenocarcinoma of gastric/GEJ, between June 1st, 2025 and the end of the recruitment period (Q3 2027)

Public study contact (from the registry)

AstraZeneca Clinical Study Information Center

877-240-9479

information.center@astrazeneca.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

6 listed

Related recruiting trials in this snapshot

RecruitingPhase 1 / Phase 2Duarte, California
Phase 1 / Phase 2: testing INBRX-106 - Hexavalent OX40 agonist antibody for Solid Tumor

This is a Phase 1/2, open-label, non-randomly assigned, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.

NCT04198766 · Official ClinicalTrials.gov record · Inhibrx Biosciences, Inc

RecruitingNot a traditional drug phaseAnchorage, Alaska
Not a traditional drug phase: Questionnaire Administration for Acute Lymphoblastic Leukemia

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

NCT05334069 · Official ClinicalTrials.gov record · Alliance for Clinical Trials in Oncology

FAQ about this NCT record

Is NCT07800754 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07800754?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07800754?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary